BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35078334)

  • 1. Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM/FLExDUX4 Mouse Model of FSHD with Systemic Antisense Therapy.
    Lu-Nguyen N; Malerba A; Antoni Pineda M; Dickson G; Popplewell L
    Hum Gene Ther; 2022 Sep; 33(17-18):923-935. PubMed ID: 35078334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
    Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
    Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.
    Lu-Nguyen N; Malerba A; Herath S; Dickson G; Popplewell L
    Hum Mol Genet; 2021 Jul; 30(15):1398-1412. PubMed ID: 33987655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.
    Lim KRQ; Bittel A; Maruyama R; Echigoya Y; Nguyen Q; Huang Y; Dzierlega K; Zhang A; Chen YW; Yokota T
    Mol Ther; 2021 Feb; 29(2):848-858. PubMed ID: 33068777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy.
    Bouwman LF; den Hamer B; van den Heuvel A; Franken M; Jackson M; Dwyer CA; Tapscott SJ; Rigo F; van der Maarel SM; de Greef JC
    Mol Ther Nucleic Acids; 2021 Dec; 26():813-827. PubMed ID: 34729250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit
    Lu-Nguyen N; Dickson G; Malerba A; Popplewell L
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of
    Lim KRQ; Maruyama R; Echigoya Y; Nguyen Q; Zhang A; Khawaja H; Sen Chandra S; Jones T; Jones P; Chen YW; Yokota T
    Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16509-16515. PubMed ID: 32601200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of
    Duranti E; Villa C
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscle eosinophilia is a hallmark of chronic disease in facioscapulohumeral muscular dystrophy.
    Nunes AM; Ramirez MM; Garcia-Collazo E; Jones TI; Jones PL
    Hum Mol Genet; 2024 May; 33(10):872-883. PubMed ID: 38340007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics.
    Chen JC; King OD; Zhang Y; Clayton NP; Spencer C; Wentworth BM; Emerson CP; Wagner KR
    Mol Ther; 2016 Aug; 24(8):1405-11. PubMed ID: 27378237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy.
    Jones T; Jones PL
    PLoS One; 2018; 13(2):e0192657. PubMed ID: 29415061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice.
    Bosnakovski D; Shams AS; Yuan C; da Silva MT; Ener ET; Baumann CW; Lindsay AJ; Verma M; Asakura A; Lowe DA; Kyba M
    J Clin Invest; 2020 May; 130(5):2465-2477. PubMed ID: 32250341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy.
    Bittel AJ; Sreetama SC; Bittel DC; Horn A; Novak JS; Yokota T; Zhang A; Maruyama R; Rowel Q Lim K; Jaiswal JK; Chen YW
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD.
    Giesige CR; Wallace LM; Heller KN; Eidahl JO; Saad NY; Fowler AM; Pyne NK; Al-Kharsan M; Rashnonejad A; Chermahini GA; Domire JS; Mukweyi D; Garwick-Coppens SE; Guckes SM; McLaughlin KJ; Meyer K; Rodino-Klapac LR; Harper SQ
    JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systemically Administered Unconjugated Antisense Oligonucleotide Targeting DUX4 Improves Muscular Injury and Motor Function in FSHD Model Mice.
    Kakimoto T; Ogasawara A; Ishikawa K; Kurita T; Yoshida K; Harada S; Nonaka T; Inoue Y; Uchida K; Tateoka T; Ohta T; Kumagai S; Sasaki T; Aihara H
    Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knocking Down DUX4 in Immortalized Facioscapulohumeral Muscular Dystrophy Patient-Derived Muscle Cells.
    Lim KRQ; Yokota T
    Methods Mol Biol; 2023; 2587():197-208. PubMed ID: 36401032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
    Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
    J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy.
    Wallace LM; Liu J; Domire JS; Garwick-Coppens SE; Guckes SM; Mendell JR; Flanigan KM; Harper SQ
    Mol Ther; 2012 Jul; 20(7):1417-23. PubMed ID: 22508491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
    Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
    Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase A activation inhibits
    Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
    J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.